Walgreens shares pop on report pharmacy chain could sell itself to PE firm Sycamore

Walgreens shares pop on report pharmacy chain could sell itself to PE firm Sycamore


People walk by a Walgreens on November 3, 2024 in Brookline, Massachusetts.

Danielle DeVries | CNBC

Shares of Walgreens jumped nearly 25% on Tuesday on a report that the company is in talks to sell itself to private equity firm Sycamore Partners. 

Walgreens and Sycamore have been discussing a deal that could be completed early next year, The Wall Street Journal reported, citing people familiar with the matter.

A Walgreens spokesperson declined to comment on the reported talks.

The report comes during a rough period for the retail pharmacy giant. The company’s stock was down more than 60% for the year before its climb Tuesday.

Walgreens – squeezed by the transition out of the Covid pandemic, a leadership shakeup, pharmacy reimbursement pressure and its wobbly push into health-care – has underperformed Wall Street’s earnings expectations for two straight quarters.

In October, Walgreens said it plans to close roughly 1,200 of its drugstores over the next three years, which includes 500 in fiscal 2025 alone. Walgreens has around 8,700 locations in the U.S., a quarter of which it says are unprofitable. The company has also scaled back its push into primary care by cutting its stake in primary-care provider VillageMD. 

Walgreens has reportedly been seen as a potential private equity target in the past. 

In 2019, private equity firm KKR made a roughly $70 billion buyout offer to the company, the Financial Times and Bloomberg reported at the time. 

This is breaking news. Please refresh for updates.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More